MedPath

Evaluation of the Safety and Efficacy of the AnapnoGuard 100 System

Not Applicable
Completed
Conditions
Intubation Complications
Interventions
Device: AnapnoGuard 100 System
Registration Number
NCT01550978
Lead Sponsor
Hospitech Respiration
Brief Summary

The purpose of this study is to evaluate the safety of using the AnapnoGuard 100 system during the course of mechanical ventilation and intubation of critical care patients in Intensive Care Unit.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Age above 21 (men and women);
  • Patient is admitted to ICU and expected to receive mechanical ventilation for more than 12 hours
  • Absence of clear signs of pneumonia and lung contusion on chest X ray;
  • For study patients, connection of the ETT to the AnapnoGuard system less than 6 hours from intubation initiation;
  • No fever or fever from a known non chest/lung origin;
Exclusion Criteria
  • Patients who had been treated with mechanical ventilation during the last 3 months;
  • Patients with facial, oropharyngeal or neck trauma
  • BMI > 40
  • Pregnant women
  • Patients ventilated in prone position
  • Difficult intubation (defined as more than 3 intubation attempts)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Study GroupAnapnoGuard 100 SystemPatients intubated with AnapnoGuard EndoTracheal Tube and connected to the AnapnoGuard 100 Control System
Primary Outcome Measures
NameTimeMethod
Rate of AE (adverse events) and SAE (serious adverse events)participants will be followed for the entire duration of intubation (an expected average of 8 days)
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Policlinico Universitario A. Gemelli

šŸ‡®šŸ‡¹

Rome, Italy

Ā© Copyright 2025. All Rights Reserved by MedPath